Jefferies Reiterates a Buy Rating on Boston Scientific Corporation (BSX), Sets a $130 PT

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to invest in for beginners. In a report released on August 11, Matthew Taylor from Jefferies reiterated a Buy rating on Boston Scientific Corporation (NYSE:BSX) with a price target of $130.00.

Was Jim Cramer Right About Boston Scientific Corporation (BSX)?

A surgeon examining a patient’s brain in an operating room, paramedics nearby.

The rating update followed the company’s release of fiscal Q2 2025 earnings on July 23, with net sales for the quarter reaching $5.061 billion and reflecting a 22.8% growth on a reported basis, 21.6% on an operational basis, and 17.4% on an organic basis, all compared to the prior year period.

Boston Scientific Corporation (NYSE:BSX) also reported GAAP net income attributable to common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago.

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.